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Abstract
Protein phosphatase 1 (PP1) binding proteins are quintessential regulators, determining substrate specificity and
defining subcellular localization and activity of the latter. Here, we describe a novel PP1 binding protein, the nuclear
membrane protein lamina associated polypeptide 1B (LAP1B), which interacts with the DYT1 dystonia protein
torsinA. The PP1 binding domain in LAP1B was here identified as the REVRF motif at amino acids 55-59. The
LAP1B:PP1 complex can be immunoprecipitated from cells in culture and rat cortex and the complex was further
validated by yeast co-transformations and blot overlay assays. PP1, which is enriched in the nucleus, binds to the N-
terminal nuclear domain of LAP1B, as shown by immunocolocalization and domain specific binding studies. PP1
dephosphorylates LAP1B, confirming the physiological relevance of this interaction. These findings place PP1 at a
key position to participate in the pathogenesis of DYT1 dystonia and related nuclear envelope-based diseases.
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Introduction
Reversible protein phosphorylation is a major mechanism
controlling key intracellular events that are essential for cell
health and viability [1-3]. Protein phosphatase 1 (PP1) is a
ubiquitous serine/threonine phosphatase that is estimated to
dephosphorylate about one third of all proteins in eukaryotic
cells [4,5]. PP1 regulates a variety of cellular functions, such as
glycogen metabolism, transcription, protein synthesis, cellular
division and meiosis [4,6,7]. In mammalian cells, three genes
encode the three PP1 isoforms: PP1alpha (PP1α), PP1Beta/
Delta (PP1β/δ) and PP1gamma (PP1γ). Furthermore, the PP1γ
gene undergoes alternative splicing to originate a ubiquitous
PP1γ1 variant and a PP1γ2 variant that is enriched in testis
[8,9]. PP1 isoforms are expressed in virtually all tissues but
exhibit different expression levels depending on the tissue, and
different subcellular distribution [9-11]. The versatility of PP1 is
largely determined by the binding of its catalytic subunit to
different specific regulatory subunits, that are responsible for
the directed targeting of PP1 to a particular subcellular
compartment and also determine its substrate specificity and
activity [4,6,7,12]. More than 200 binding/regulatory subunits
have been already described, making PP1 an essential protein
in many distinct cellular processes [2,13]. Most PP1 binding
proteins interact with the PP1 catalytic subunit through a
conserved PP1 binding motif termed the RVxF motif, which has
the consensus sequence [R/K] XA(0-1) [V/I] XB [F/W], where XA is
any amino acid and XB is any amino acid except proline [14].
More recently, other consensus sequence have been proposed
for the RVxF motif: [HKR]-[ACHKMNQRSTV]-V-[CHKNQRST]-
[FW] [15] and [KRL] [KRSTAMVHNQ] [VI] {FIMYDP} [FW] [16].
The binding of PP1 to regulatory proteins through the RVxF
motif does not cause major effects on the conformation and
activity of PP1, but mediates the initial anchoring of regulatory
subunits and thereby promotes the interaction at secondary
binding sites [7,16,17]. Subsequently other PP1 binding motifs
have also been reported, such as the apoptotic signature F-X-
X-[KR]-X-[KR] [18], the SILK and the MyPhoNE motifs [16].
The existence of these conserved binding sites within
regulatory subunits explains the ability of PP1 catalytic subunit
to interact with numerous regulatory proteins and consequently
the binding of most regulatory subunits is mutually exclusive
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[7]. Since the regulatory subunits control the specificity and the
diversity of PP1 activity, the key to understanding PP1 function
lies in studying these regulatory subunits and their cellular
functions. Several yeast two-hybrid (YTH) screens of a human
brain cDNA library were performed using the three PP1
isoforms (PP1α, PP1γ1 and PP1γ2) as baits. From each
screen many positive clones were identified encoding several
different proteins. Among them, were proteins already known
as PP1 regulators and also novel putative PP1 regulators
[19,20]. The majority of the novel putative PP1 regulators
comprise at least one of the conserved PP1 binding motifs.
One of the novel PP1 regulators isolated in the three
independent YTH screens was torsinA interacting protein 1
(TOR1AIP1) or lamina associated polypeptide 1B (LAP1B).
LAP1B belongs to a family of integral proteins of the inner
nuclear membrane, named lamina associated polypeptide 1
(LAP1). Members of the LAP1 family (LAP1A, B and C) were
initially identified using monoclonal antibodies generated
against lamina-enriched fractions of rat liver nuclei [21]. The
three LAP1 isoforms result from alternative splicing of the
TOR1AIP1 gene [22] and have been poorly studied. Moreover,
the cDNA for LAP1B isoform was, to date, the only human
isoform completely sequenced [23]. The function of LAP1B is
poorly understood but it is known that it binds to lamins and
chromosomes and that it is phosphorylated during interphase
and mitosis [24]. As indicated by the nomenclature, LAP1 was
found to interact with torsinA [25,26], the central protein of a
neurologic disorder known as DYT1 dystonia [27]. However,
the physiological relevance of this novel complex has not yet
been determined. In the present study we validated the novel
complex LAP1B:PP1 using several in vitro and in vivo
techniques, namely a blot overlay assay, co-
immunoprecipitation (co-IP) and yeast co-transformation.
Furthermore, the PP1 binding motif responsible for the
interaction was mapped. The functional relevance of this
complex was pursued and we determined that LAP1B is
dephosphorylated by PP1 in vitro.
Materials and Methods
Antibodies
The primary antibodies used were rabbit polyclonal LAP1
[25]; rabbit polyclonal CBC2C and CBC3C, that recognizes the
C-terminal of PP1α and PP1γ, respectively [9]; rabbit polyclonal
lamin B1 (Santa Cruz Biotechnology); 6×His-tag antibody
(Novagen), that recognizes 6×His-tag-proteins; and Myc-tag
antibody (Cell Signaling), that recognizes Myc-fusion proteins.
The secondary antibodies used were anti-mouse and anti-
rabbit horseradish peroxidase-linked antibodies (GE
Healthcare) for ECL detection, and FITC-conjugated anti-
mouse IgG (Molecular Probes) and Alexa 594-conjugated anti-
rabbit IgG (Molecular Probes) for co-localization studies.
Expression vectors and DNA constructs
For yeast co-transformation assays, PP1α, PP1γ1, PP1γ2
and the specific C-terminal of PP1γ2 (PP1γ2End) cDNAs were
cloned into the pAS2-1 (Clontech), in frame with the GAL4-
binding domain, as described in Esteves et al, 2012 [19,20].
pACT2-LAP1B (in frame with the GAL4 activation domain) was
obtained from a human brain cDNA library (Clontech,
HL4004AH) [19,20]. LAP1B binding motif (BM) deletion
mutants comprising amino acids 1-209 (LAP1B-BM1), 61-508
(LAP1B-BM2), 1-508 (LAP1B-BM1/2) and 238-584 (LAP1B-
BM3) were prepared by PCR amplification with appropriate
primers (Table S1). The amplified fragments were subcloned
into the EcoRI/XhoI restriction sites of the pACT2 vector
(Clontech). The same methodology was used to clone
additional LAP1B deletion mutants comprising amino acids
1-338 (LAP1B-BM1/2-TM), 1-369 (LAP1B-BM1/2+TM),
332-584 (LAP1B-BM3-TM) and 365-584 (LAP1B-BM3+TM)
into the pET-28c vector (Novagen). Full-length LAP1B and the
mutants 1-209 (LAP1B-BM1) and 61-508 (LAP1B-BM2) in the
pACT2 vector were subcloned into the pET-28c vector. Full-
length LAP1B and LAP1B-BM2 and LAP1B-BM3 in the pACT2
vector were also subcloned into the mammalian expression
vector pCMV-Myc (Clontech) to obtain a Myc-fusion protein.
Additionally a LAP1B (ΔA185) mutation was introduced into
pET-LAP1B by site-directed mutagenesis using the primers
described in Table S1. The constructs were all verified by DNA
sequencing using an ABI PRISM 310 Genetic Analyzer
(Applied Biosystems, Porto, Portugal).
Yeast co-transformation analysis
Each of the bait plasmids (pAS2-1-PP1α, pAS2-1-PP1γ1,
pAS2-1-PP1γ2 or pAS2-1-PP1γ2end) was co-transformed with
one of the specific target proteins; pACT-LAP1B or its deletions
mutants (pACT-BM1, pACT-BM2, pACT-BM1/2 and pACT-
BM3), into the yeast strain AH109 by the lithium acetate
method (according to the manufacturer’s instructions,
Clontech). In parallel, co-transformations of the vectors pAS2-1
and pACT2 were performed as a negative control. The
association of murine p53 (encoded by plasmid pVA3-1) and
SV40 large T antigen (plasmid pTD1) was used as a positive
control. The transformants were assayed for HIS3, ADE2 and
MEL1 reporter genes. All positive clones were replated in
SD/QDO medium containing X-α-Gal and incubated at 30°C for
2-4 days.
Expression of recombinant proteins in Escherichia coli
Escherichia coli Rosetta cells (DE3) were transformed with
one of the pET-LAP1B constructs and grown overnight in 5 mL
of Luria-Bertani/Kanamycin medium at 37°C. Aliquots (500 µL)
were transferred to 50 ml of Luria-Bertanini/Kanamycin until the
OD600 was around 0.5-0.6. Expression was induced by adding
1 mM isopropyl-β-D-thiogalactopyranoside (IPTG) to the
culture at 37°C for different periods of time (1, 3 and 5 hours)
with shaking. Cells were recovered by centrifugation (4000 rpm
for 10 min), resuspended in 500 µL of 1x PBS and lysed by
sonication. Cells were then centrifuged (13200 rpm for 30 min),
the supernatant was transferred to a new microtube (soluble
fraction) and the pellet resuspended in 500 µL of boiling 1%
SDS (insoluble fraction).
Blot overlay assays
LAP1B deletion mutants.  Bacterial extracts, prepared as
described above, were separated on a 10% SDS-PAGE and
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the proteins were subsequently transferred to a nitrocellulose
membrane. The membrane was overlaid with 1 µg/mL of
purified recombinant PP1γ1 protein [28]. After washing to
remove excess protein, bound PP1γ1 was detected by
incubating the membrane with PP1γ antibody and developed
by enhanced chemiluminescence (ECL, GE Healthcare).
LAP1B isoforms.  LAP1B and LAP1B (ΔA185) proteins
were generated by in vitro transcription/ translation (IVT) from
pET-LAP1B and pET-LAP1B(ΔA185) expression vectors,
respectively, using the TnT-coupled transcription/translation kit
(Promega), according to the manufactures’ instructions. For the
overlay assays, two samples of 250 ng of purified recombinant
PP1γ1 protein [28] were separated on a 12% SDS-PAGE. Both
proteins were transferred to a nitrocellulose membrane but one
was overlaid with LAP1B-IVT, while the other was overlaid with
LAP1B (ΔA185)-IVT. The bound proteins were detected by
incubating the membrane with LAP1 antibody and developed
by ECL.
Cell culture and transfection
COS-7 (ATCC CRL-1651) and HEK293 (ATCC CRL-1573)
cells were grown in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% Fetal Bovine Serum (FBS),
100 U/ml penicillin, 100 mg/ml streptomycin and 3.7 g/l
NaHCO3 (Complete DMEM). SH-SY5Y cells (ATCC CRL-2266)
were grown in Minimal Essential Medium (MEM) supplemented
with F-12 Nutrient Mixture (Gibco, Invitrogen), 10% FBS
(Gibco, Invitrogen), 1.5 mM L-glutamine, 100 U/mL penicillin
and 100 mg/mL streptomycin (Gibco, Invitrogen). HeLa cells
(ATTC CRM-CCL-2) were grown in Minimal Essential Medium
(MEM) with Earle’s salts and GlutaMAX (MEM), supplemented
with 10% fetal bovine serum, 1% MEM Non-Essential amino
acids and 100 U/mL penicillin and 100 mg/mL streptomycin. All
cultures were maintained at 37°C and 5% CO2. Transient
transfections of COS-7 and HeLa cells were performed using
LipofectAMINE 2000 (Invitrogen Life technologies). After 24
hours of transfection, cells were harvested for subsequent
immunoprecipitation (IP) experiments or were fixed, using 4%
paraformaldehyde, for immunocytochemical analysis.
Brain dissection
Winstar rats (9-12 weeks) were obtained from Harlan
Interfaune Ibérica, SL. All experimental procedures observed
the European legislation for animal experimentation (2010/63/
EU). No specific ethics approval under EU guidelines was
required for this project, since the rats were only euthanized, by
cervical stretching followed by decapitation, for brain removal.
This is within the European law (Council Directive 86/609/EEC)
and during this procedure we took all steps to ameliorate
animal suffering and used the minimum number of animals
possible. The procedures were approved and supervised by
our Institutional Animal Care and Use Committee (IACUC):
Comissão Responsável pela Experimentação e Bem-Estar
Animal (CREBEA).
Briefly, animals were euthanized by cervical stretching
followed by decapitation and the cortex was dissected out on
ice. The tissue was then homogenized on ice, in non-
denaturing lysis buffer (50 mM Tris-HCl pH 8.0, 120 mM NaCl,
4% CHAPS) containing protease inhibitors (1 mM PMSF, 10
mM Benzamidine, 2 µM Leupeptin, 1.5 µM Aprotinin, 5 µM
Pepstatin A), with a Potter-Elvehjem tissue homogenizer with
10-15 pulses at 650-750 rpm [29]. Resulting tissue extracts
were used for IP analysis using Dynabeads Protein G (Dynal,
Invitrogen) as described below.
Co-immunoprecipitation
COS-7 cells transfected with Myc-LAP1B were collected in
lysis buffer (50 mM Tris-HCl pH 8, 120 mM NaCl, 4% CHAPS)
containing protease inhibitors (1 mM PMSF, 10 mM
Benzamidine, 2 µM Leupeptin, 1.5 µM Aprotinin, 5 µM
Pepstatin A). Dynabeads Protein G (Dynal, Invitrogen) were
washed in 3% BSA/1x PBS. Primary antibodies were cross-
linked to Dynabeads according to the manufacter’s protocol.
Cell lysates were precleared with 20 µL (0.6 mg) Dynabeads
for 1 hour and then incubated with antibody-dynabeads for 2h
at 4°C. The immunoprecipitates were washed in 1x PBS and
proteins eluted by boiling in loading buffer before SDS-PAGE
and immunoblotting analysis. For analysis of endogenous
proteins, COS-7 cells and SH-SY5Y cells were collected in
lysis buffer and immunoprecipitated as described above, but
cell lysates were incubated with antibody-dynabeads overnight
at 4°C. HEK293 immunoprecipitation was carried out as
previously described [30]
Immunocytochemistry
Once fixed as described above, HeLa cells were
permeabilized with methanol for 2 min. Cells were first
incubated with one of the primary antibodies (anti-PP1γ or
PP1α) for 2 hours, followed by Alexa 594-conjugated
secondary antibody. After washing with 1x PBS, cells were
subsequently incubated with a second primary antibody (anti-
myc) for 2 hours, followed by anti-mouse fluorescein
isothiocyanate (FITC) conjugated secondary antibody.
Preparations were washed with PBS, mounted using
Vectashield mounting media with DAPI (Vector) and visualized
using an LSM510-Meta confocal microscope (Zeiss) and a
63x/1.4 oil immersion objective. The argon laser lines of 405
nm, 488 nm, and a 561nm DPSS laser were used.
Microphotographs were acquired in a sole section in the Z-axis
(xy mode) and represent a mean of 16 scans. Profiles were
acquired using the Zeiss LSM 510 4.0 software as previously
described [29,31].
In vitro dephosphorylation of LAP1B
SH-SY5Y cells were treated with 0.25 nM or 500 nM okadaic
acid (OA) for 3 hours. Then, cells were collected in lysis buffer
(50 mM Tris-HCl pH 8, 120 mM NaCl, 4% CHAPS, 250 mM
EDTA, 1 mM sodium orthovanadate, 5 mM sodium fluoride)
containing protease inhibitors (1 mM PMSF, 10 mM
Benzamidine, 2 µM Leupeptin, 1.5 µM Aprotinin, 5 µM
Pepstatin A) and immunoprecipitated with LAP1 antibody, as
described above. Immunoprecipitates were incubated at 30°C
for 1 hour with or without 100 ng of purified PP1γ1 protein in
PP1 buffer (50 mM Tris-HCl pH 7.5, 0.1 mM EGTA, 1 mM
MnCl2, 5 mM DTT). Samples were further analyzed by 7.5%
SDS-PAGE followed by immunoblotting.
LAP1B Is a Novel PP1 Regulatory Protein
PLOS ONE | www.plosone.org 3 October 2013 | Volume 8 | Issue 10 | e76788
SDS-PAGE and Immunoblotting
Samples were separated on SDS-PAGE and
electrophoretically transferred onto nitrocellulose, followed by
immunological detection with specific antibodies as indicated.
Membranes were saturated in 5% non-fat dry milk in TBS-T for
3 hours and further incubated with primary antibodies. The
incubations with the CBC2C, CBC3C and LAP1 antibodies
were performed overnight. The incubations with the His-tag
and Myc-tag antibodies were carried out for 2 hours. Detection
was achieved using horseradish peroxidase-conjugated anti-
rabbit or anti-mouse IgGs as secondary antibodies and
proteins visualized by ECL (GE Healthcare).
Results
Identification of LAP1B as a novel putative PP1
regulatory protein
In order to identify novel potential PP1 regulatory proteins,
the three PP1 isoforms (PP1α, PP1γ1 and PP1γ2) were used
as baits to screen a human brain cDNA library by the YTH
system. From these screens 298, 241 and 228 positive clones
were identified using PP1α, PP1γ1 and PP1γ2 as baits,
respectively [19,20]. Detailed analysis revealed 14, 4 and 2
positive clones, encoding a potentially novel PP1 regulatory
protein - LAP1B, for the PP1α, PP1γ1 and PP1γ2 screens,
respectively (Table S2) [32]. Sequencing of the identified
clones determined that all correspond to the LAP1B variant 1,
recently reported in the GenBank database
(NM_001267578.1). The variant 1 differs from the variant 2
(NM_015602) only by a CAG insertion, which results in an
additional alanine in the coding sequence, otherwise the
sequence is identical to the first human LAP1B sequence
reported in 2002 [23]. Moreover, others reports showed that
TOR1AIP1 gene possesses a 3’ tandem splice site, TAGCAG,
at the exon 3 boundary, which results in an amino acid
insertion or deletion in the encoded protein [33,34]. From all
LAP1B clones obtained we selected a full-length clone (clone
135; Table S2) for further studies. The latter comprises a short
5’ untranslated region followed by the ATG start codon, an
open reading frame of 2000 nucleotides, that encodes 584
amino acids, followed by a stop codon and a short 3’
untranslated region (Figure 1A). LAP1B was previously
described as a type 2 integral membrane protein, with an N-
terminal nucleoplasmic domain, one predicted transmembrane
domain (TM) and a C-terminal lumenal domain [23]. Our in
silico analysis also revealed that LAP1B has three conserved
PP1 binding motifs (BM): REVRF (amino acids 55-59), KVNF
(amino acids 212-215) and KVKF (amino acids 538-541), that
were called BM1, BM2 and BM3, respectively. BM1 and BM2
are localized in the nucleoplasm, while BM3 is localized in the
lumen of the perinuclear space. Additionally, a second generic
PP1 binding motif termed SILK (amino acids 306-309) was also
identified (Figure 1A). Further in silico characterization of these
four potential PP1 binding motifs (BM1, BM2, BM3 and SILK)
was achieved using the ClustalW algorithm, which allowed for
the determination of the homology between species (Figure
1B). Interestingly, the BM1 and BM3 are totally conserved
motifs among the species analyzed (Human, Chimpanzee,
Orangutan, Mouse, Rat). The other binding motifs (BM2 and
SILK) are also completely conserved between Human,
Chimpanzee and Orangutan but do deviate markedly in mouse
and rat; with two residues common to all species in the SILK
domain and only one residue is common to all species for the
BM2 domain (Figure 1B). Subsequent to the in silico LAP1B
characterization, the novel LAP1B:PP1 complex was validated
in vitro and in vivo.
LAP1B and PP1 interact in vitro
The in vitro validation of this novel complex as well as the
identification of the binding motif responsible for the interaction
was accomplished using a blot overlay assay. Several deletion
mutants were prepared as described above, each comprising
at least one of the PP1 binding motifs as represented in Figure
2A. The importance of the TM was also addressed by
evaluating the binding in the presence or absence of the latter
(Figure 2A). Thus, both full-length LAP1B and the different
deletion mutants were expressed in bacteria as 6×His-tag
fusion proteins by adding 1 mM IPTG to the growing cultures at
37°C. All recombinant proteins (full-length and mutants) were
efficiently expressed in bacteria, including the deletion mutants
with or without the TM domain (data not shown). The proteins
thus expressed were used to carry out the blot overlay assay.
Briefly, the different recombinant proteins were separated by
SDS-PAGE and electrotransferred onto nitrocellulose
membranes. Recombinant protein detection was achieved with
the His-tag antibody (Figure 2B) and for the overlay assay the
purified PP1γ1 protein was applied (Figure 2C). The negative
controls used included the pET-28c vector without an insert or
with a non-induced insert. As a positive control the pET28c-
Nek2A was used, given that Nek2A is a well known protein that
strongly interacts with PP1 [35]. The immunoblotting using His-
tag antibody (Figure 2B) of both full-length and deletion
mutants revealed that all the expressed proteins have the
expected molecular weight as indicated in Figure 2A. Additional
bands were sometimes detected for LAP1B, LAP1B-BM1 and
LAP1B-BM2, these could possibly correspond to proteolytic
fragments (Figure 2B). The overlay assays revealed increased
PP1γ1 binding concomitant with increasing amounts of
recombinant full-length LAP1B (Figure 2C). Additionally, we
also demonstrated that PP1γ1 binds to the deletion mutant that
comprises the residues 1-209 encompassing the BM1, and
also to the construct that comprises both BM1 and BM2 with or
without the TM (Figure 2C). However, PP1γ1 does not bind to
the recombinant protein comprising only the BM2 or the BM3
(Figure 2C). Thus, using in vitro techniques we established that
LAP1B binds to PP1γ1 through the BM1 (REVRF).
The novel complex LAP1B:PP1 is also formed in vivo
Having shown that the LAP1B:PP1 complex is formed in vitro
the ability of the same to be formed in vivo was addressed.
Yeast co-transformations were carried out in order to validate
the novel complex formation and to simultaneously confirm
relevant domains in LAP1B for the interaction, as well as to test
different PP1 isoforms. Firstly, co-transformations were carried
out with full-length LAP1B and different PP1 isoforms (α, γ1 or
γ2), the assay took advantage of α-Galactosidase activity in the
LAP1B Is a Novel PP1 Regulatory Protein
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Figure 1.  Human LAP1B sequence and domains.  A- Nucleotide and corresponding amino acid sequence of human LAP1B
encoded by clone 135. Stop and start codons are coloured blue. The three well conserved PP1 binding motifs (RVxF) are
highlighted in red (positions 55-59, 212-215 and 538-541 in aa sequence) and a second generic PP1 binding motif (SILK) is
coloured green (position 306-309 in aa sequence). The transmembrane domain is highlighted in orange (position 339-361 in aa
sequence). B- Schematic illustration of LAP1B domains. Sequence of human LAP1B was aligned against others species using
ClustalW algorithm. Sequence conservation is indicated by asterisks (identical sequences), colons (conserved substitutions) and
periods (semi-conserved substitutions). BM1, BM2 and BM3, RVxF-like PP1 binding motif 1, 2 and 3, respectively; INM, inner
nuclear membrane; ONM, Outer nuclear membrane; SILK, a second generic PP1 binding motif; TM, transmembrane domain.
doi: 10.1371/journal.pone.0076788.g001
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Figure 2.  Blot overlay assay with PP1γ1.  Immunoblotting analysis using a His-tag antibody is also shown.
A-Schematic representation of LAP1B deletion mutants cloned into the pET-28c vector. The expected molecular weight (MW) of
each construct is indicated. The red boxes represent the RVxF motifs, the green boxes correspond to the SILK motif, and the yellow
boxes represent the transmembrane domain. B- Blot overlay assay of full-length LAP1B. Increasing amounts of recombinant full-
length LAP1B (12, 24 and 48 µL) were loaded on each well as indicated. C- Blot overlay assay of LAP1B deletion mutants. Deletion
mutants: 1, LAP1B–BM1; 2, LAP1B–BM2; 3, LAP1B–BM1/2+TM; 4, LAP1B–BM1/2-TM; 5, LAP1B-BM3+TM; 6, LAP1B-BM3-TM.
Non-induced (NI) and pET-28c vector without an insert (pET) were used as negative controls and Nek2A (Nek) as positive control.
Bacterial cultures were collected 3 hours after IPTG (1mM) induction at 37°C.
doi: 10.1371/journal.pone.0076788.g002
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presence of the blue chromogenic substrate X-α-gal, producing
a blue colour in the event of an interaction. The results (Figure
3) clearly show that LAP1B interacts with all PP1 isoforms
tested (PP1α, PP1γ1 and PP1γ2; Figure 3A) but does not
interact with the C-terminal portion of PP1γ2 isoform
(PP1γ2end; Figure 3A). Subsequently, the relevant domain in
LAP1B for the interaction was again tested using the in vivo
conditions. These LAP1B deletion mutants, previously
produced, were co-transformed in yeast with the PP1γ1
isoform and the results are presented in Figure 3B.
Unequivocally, the results were positive for the deletion mutant
that comprises the residues 1-209 including the BM1 (Figure
3B) and also with the construct that comprises both BM1 and
BM2 (BM1/2). In sharp contrast the results were negative with
the LAP1B-BM2 and LAP1B-BM3 (Figure 3B). The positive and
negative controls are presented in Figure 3C. These results
show that it is the BM1 (REVRF) that mediates the interaction
between LAP1B and PP1.
Additionally, the in vivo occurrence of the complex was
further investigated and distinct models were used, namely a
non-neuronal cell line (COS-7), a neuronal-like cell line (SH-
SY5Y) and rat brain. Thus, co-IPs using the specific antibodies
against PP1α, PP1γ and LAP1B were carried out. Firstly,
COS-7 cells were transfected with Myc-LAP1B and Myc-
LAP1B deletion mutants (LAP1B-BM2 and LAP1B-BM3) and
further immunoprecipitated using the PP1γ antibody (Figure
4A). The Myc-LAP1B deletion mutants are similar to those
tested in yeast co-transformation assays. Our results showed
that PP1γ binds only to the full-length LAP1B but not to LAP1B
deletion mutants (LAP1B-BM2 and LAP1B-BM3). Once more
our results clearly showed that PP1γ only binds LAP1B when
the BM1 is present. Non-transfected COS-7 (Figure 4B) and
SH-SY5Y (Figure 4C) cellular extracts were also
immunoprecipitated with PP1α and PP1γ antibodies. Rat
cortical extracts were also immunoprecipitated with the same
antibodies as well as with the LAP1 antibody and the results
are presented in Figure 4D. Endogenous LAP1B was also
Figure 3.  Yeast co-transformation assay in SD/QDO/X-α-gal medium.  Full-length LAP1B and its deletion mutants cloned in the
pACT2 vector are represented. The red boxes represent the RVxF motifs present in the constructs, the green boxes correspond to
the SILK motif, and the yellow boxes represent the transmembrane domain. A- Positive interactions were observed between LAP1B
and PP1α, PP1γ1 and PP1γ2, but not with the C-terminus of PP1γ2 (PP1γ2End). B- PP1γ1 interacted with LAP1B-BM1 and BM1/2
but not with LAP1B-BM2 and BM3. C- Association of murine p53 and SV40 large T antigen was used as positive control (+) and co-
transformation of pAS2-1 and pACT2 vectors as negative control (-).
doi: 10.1371/journal.pone.0076788.g003
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detected after IP with PP1α and PP1γ in COS-7 cells (Figure
4B) and SH-SY5Y cells (Figure 4C). Finally, using rat cortical
brain extracts we confirmed that the LAP1B:PP1 complex is
also formed in brain, since we detected LAP1B after IP with
PP1α or γ antibodies. Further, when we immunoprecipitated
with LAP1 antibody we could also detect both PP1 isoforms
(Figure 4D). The complex was also detected in other brain
regions, namely rat striatum and cerebellum (data not shown)
were PP1 is highly abundant.
Both LAP1B isoforms bind to PP1
Thus far we have unequivocally shown that LAP1B is a novel
PP1 regulatory protein and that the complex formed by the two
proteins can occur both in vitro and in vivo. Given the high
Figure 4.  Co-immunoprecipitation of the PP1:LAP1B complex in COS-7 cells, SH-SY5Y cells and rat cortex.  A- COS-7 cells
were transfected with Myc-LAP1B, Myc-LAP1B-BM2 or Myc-LAP1B-BM3 and immunoprecipitated with PP1γ bound to protein G-
DynaBeads. B- Non-transfected COS-7 cells were immunoprecipitated with PP1γ or PP1α antibodies bound to protein G-
Dynabeads. C-SH-SY5Y cells were immunoprecipitated with PP1γ or PP1α antibodies bound to protein G- Dynabeads. D- Rat
cortex extracts were immunoprecipitated with PP1γ, PP1α or LAP1 antibodies bound to protein G- Dynabeads. The negative
controls were performed by incubating cell extracts with beads. IP, immunoprecipitation. IB, immunoblotting.
doi: 10.1371/journal.pone.0076788.g004
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degree of similarity between both LAP1B variants and the fact
that both comprise the BM1 (REVRF) responsible for the
interaction, it is reasonable to deduce that both variants interact
with PP1. In order to confirm this hypothesis we generated, by
site directed mutagenesis, the LAP1B (ΔA185) construct that
corresponds to LAP1B variant 2 reported in GenBank. The
interaction of both LAP1B isoforms with PP1 was indeed
confirmed by in vitro overlay assay. Briefly, 250 ng of
recombinant purified PP1γ1 protein were separated by SDS-
PAGE and electrotransferred to a nitrocelulose membrane that
was subsequently overlaid with each of the LAP1B variants. As
expected both LAP1B variants are able to interact with PP1γ1
since we can detect a band of approximately 37 kDa (Figure 5)
that corresponds to the molecular weight of PP1γ1.
Localization of the LAP1B:PP1 complex
Given the confirmation that this novel complex is formed in
vivo, it is evident that these two proteins are functionally related
and therefore it becomes important to describe their
localization. Co-localization of both proteins indicated that the
complex exists in vivo and has physiological relevance. HeLa
cells were transiently transfected with Myc-LAP1B and
subjected to immunocytochemistry using a Myc-tag antibody.
The Myc-LAP1B was mainly found in the nuclear envelope and
also in the nucleus where it co-localizes with lamin B1 (Figure
6A). Endogenous PP1γ and PP1α were detected using specific
antibodies. All proteins have the expected subcellular
distribution; each has been previously described individually
[10,21,23]. The PP1γ was found predominantly in the nucleus,
including the nucleolus, and throughout the cytoplasm (Figure
6B). The PP1α was also found predominantly in nucleus,
excluding the nucleolus, and throughout the cytoplasm (Figure
6B). Despite the quite different subcellular distribution of
LAP1B and PP1 isoforms it is evident that they co-localize at
specific points within the nucleus and very near to the nuclear
envelope, as observed by the yellow color indicated in the
ROIs (Figure 6B). The co-localizing points were confirmed by
confocal profiling (denoted with *), where we demonstrated that
the fluorescence intensity of the two channels correlated,
particularly in those points, through the white line represented
Figure 5.  Blot overlay assay of LAP1B variants.  Two
samples of purified recombinant PP1γ protein were separated
by SDS-PAGE and the resulting blot was overlaid with LAP1B-
IVT (1) or LAP1B (ΔA185)-IVT (2). IB, immunoblotting.
doi: 10.1371/journal.pone.0076788.g005
in the image (Figure 6C and D). The co-localization quantitative
analysis was performed (Figure 6E) using a specific co-
localization software (Zeiss LSM 510 4.0 software) as
previously described [29,31]. Essentially, LAP1B co-localizes
similarly with both PP1 isoforms (27.6 ± 0.65% and 27.1 ±
0.8% with PP1γ and PP1α, respectively). The percentage of
PP1γ and PP1α that co-localize with LAP1B is lower (13.5 ±
0.48 and 13.8 ± 0.8, respectively).
PP1 specifically binds to LAP1B
Many nuclear membrane proteins are primarily or ultimately
linked to each other via direct or indirect interactions involving
the nuclear lamina. To test the specificity of the LAP1B:PP1
complex we tested whether other inner nuclear membrane
proteins (NPC62, emerin and LAP2β) also bound to PP1. Co-
IPs were performed using PP1 antibody and the potential
binding partners were further screened using specific
antibodies (Figure 7). The results presented, clearly show that
PP1 only binds to LAP1 and not to the other proteins tested
(NPC62, emerin and LAP2β). These results strengthen our
hypothesis that LAP1 and PP1 are functionally associated,
since they bind specifically in regions near the nuclear
envelope (Figure 6).
LAP1B is a novel substrate for PP1
It is well established that PP1 versatility is largely determined
by its regulatory proteins. The latter define subcellular
targeting, substrate specificity and even the activity PP1.
Having determined that LAP1B is a novel PP1 regulatory
protein, since the complex is formed both in vitro and in vivo
and the two proteins co-localize in human cell lines, it is
reasonable to deduce that the two proteins are functionally
associated. We went on to test if LAP1B is a substrate for PP1,
given that LAP1B can be phosphorylated at several residues
[36-38]. SH-SY5Y cells were incubated with two different
concentrations of OA (a protein phosphatase inhibitor),
followed by IP with LAP1 antibody and further incubation with
recombinant purified PP1γ1 protein (Figure 8). Analysis of
Figure 8 showed that when we inhibit PP2A and PP1 (500 nM
OA) a slight decrease in the migration of LAP1B is detected,
consistent with an increase in its protein phosphorylation level,
this is not evident when only PP2A is inhibited (0.25 nM OA)
(Figure 8, lysates). In contrast, when we immunoprecipitate
LAP1B from cells treated with 500 nM OA and incubated the
resulting immunoprecipitates with 100 ng of purified PP1γ1
protein (Figure 8, IP) a clear shift in the opposite direction is
observed, indicating an in vitro dephosphorylation by PP1γ1.
Discussion
PP1 regulates numerous cellular functions by binding to
different regulatory subunits, which are, in turn, responsible for
the targeting of PP1 to a particular subcellular compartment,
but also determine substrate specificity and activity [4,6,7,12].
In this study we show that LAP1B is a novel PP1 regulatory
protein. This LAP1B interaction was originally identified in YTH
screens of a human brain cDNA library using three PP1
isoforms (α, γ1 and γ2) as baits [19,20]. Moreover, LAP1B
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Figure 6.  Subcellular distribution of the LAP1B:PP1 complex in HeLa cells.  HeLa cells were transfected with Myc-LAP1B and
then processed for immunocytochemistry using specific antibodies to Myc-tag and endogenous lamin B1 and PP1γ and α isoforms.
A- Immunolocalization of both myc-LAP1B and lamin B1. B- Immunolocalization of myc-LAP1B and PP1γ and α isoforms. The
presence of the complexes is evidenced by the ROI (region of interest). C, D- Confocal profiles representing the green fluorescence
intensity (FITC-conjugated secondary antibody labelling Myc-LAP1B) and the red fluorescence intensity (Alexa Fluor 594-
conjugated secondary antibody labelling PP1γ [C] or PP1α [D]) in a specific distance (arrow); asterisks denote co-localizing points.
E- Quantification of % of co-localization between LAP1B and PP1 isoforms. Values are mean ± SEM, n= 75 cells (for PP1γ) and 55
cells (for PP1α). Photographs were acquired using a LSM 510-Meta confocal microscope. Bars, 10 µm.
doi: 10.1371/journal.pone.0076788.g006
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variant 1, from all these screens, was isolated and fully
sequenced [32]. In each case the variant obtained was the one
recently reported in the GenBank database (NM_001267578)
and differs from the LAP1B variant 2 (NM_015602) by only a 3
Figure 7.  Co-immunoprecipitation of PP1 binding proteins
at the nuclear envelope.  HEK293 cells were
immunoprecipitated with PP1 antibody bound to protein A-
sepharose beads. The negative controls were performed by
incubating cell extracts with beads. IP, immunoprecipitation. IB,
immunoblotting.
doi: 10.1371/journal.pone.0076788.g007
Figure 8.  In vitro dephosphorylation of LAP1B.  SH-SY5Y
cells were incubated with 0, 0.25 or 500 nM okadaic acid (OA)
for 3 hours and immunoprecipitated with LAP1 antibody.
Immunoprecipitates were incubated at 30°C for 1 hour with or
without 100 ng of PP1γ1 protein. The negative controls were
performed by incubation of cells extracts with beads. In the left
panel are presented the cell lysates correspondent of each
condition immunoprecipitated (right panel). IP,
immunoprecipitation. IB, immunoblotting.
doi: 10.1371/journal.pone.0076788.g008
nucleotide (CAG) insertion, which results in the introduction of
a single alanine residue at position 185 of the coding
sequence. Typically such variants are generated by alternative
splicing [28,33] and this has been shown to be so for the
TOR1AIP1 gene. Despite this subtle difference, both LAP1B
variants have the same conserved PP1 binding domains and
bind to PP1 (Figure 5). Consistent with the YTH results the
data here presented, for the yeast co-transformation assays,
confirmed that LAP1B is able to bind to all the PP1 isoforms
tested (α, γ1 and γ2), but not to the C-terminus of PP1γ2
isoform (Figure 3). Thus, this novel LAP1B:PP1 complex was
validated not only in vivo but also in vitro by a blot overlay
assay (Figure 2). LAP1 is expressed in both non-neuronal and
neuronal tissues [30], as are PP1α and PP1γ1; even though
the latter has higher expression levels in brain [9]. Thus, we
performed co-IP assays in COS-7 cells (non-neuronal cell line),
SH-SY5Y cells (neuronal-like cell line) and rat cortex (Figure
4). Moreover, the complex LAP1B:PP1 was also found in rat
hippocampus and striatum, regions where PP1α and PP1γ are
particularly enriched (data not shown)
LAP1B is not a well characterized protein and its main
cellular function remains to be defined. However, it is an
integral membrane protein of the inner nuclear membrane that
interacts with lamins and chromosomes and this is functionally
relevant for the maintenance of the nuclear architecture during
interphase and mitosis [24]. Recently, it was demonstrated that
LAP1 recruits torsinA to the nuclear envelope [25], although the
latter is normally located at the endoplasmic reticulum. In
contrast, a torsinA mutant form (ΔE302/303-torsinA), which is
present in DYT1 dystonia patients, is primarily relocated to the
nuclear envelope [39,40]. Protein: protein interactions can be
regulated by protein phosphorylation and consequently by
protein kinases and phosphatases. It is therefore highly
relevant that LAP1B should bind to PP1. Thus, several LAP1B
deletion mutants were generated to determine the binding
region responsible for the binding to PP1. In silico analysis
revealed that LAP1B has three potential PP1 binding RVxF
motifs: REVRF (amino acids 55-59) and KVNF (amino acids
212-215) located in the nucleoplasm and KVKF (amino acids
538-541) located in the lumen of the perinuclear space. An
additional generic PP1 binding motif termed SILK (Figure 1) is
also present in the nucleoplasmic domain. We defined that
LAP1B:PP1 interaction occurs primarily through a region that
comprises the REVRF domains (BM1). These results (Figures
2C, 3B, 4A) support an interaction, which in topological terms
provides physiological relevance, given that the BM1 is located
in the nucleoplasmic portion of LAP1B and PP1 is particularly
abundant in the nucleus. The BM2 and the SILK motif are also
located in the nucleoplasm but our results clearly showed that
these motifs do not mediate the interaction between LAP1B
and PP1. BM3 is located in the perinuclear space making this
an unlikely domain for the association of both proteins.
Moreover, BM1 is conserved among different species (Figure
1B) while BM2 and SILK are not. Another remarkable aspect is
that RVxF motif is often N-terminal flanked by basic residues
and C-terminal flanked by acidic residues and this affects the
binding affinity for the RVxF motif [14]. Concordantly, BM1 is
preceded by basic residues (arginine) and followed by acidic
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residues (aspartic and glutamic acid) (Figure 1B). Further, the
SILK motif is always N-terminal to the RVxF motif [16], but this
is not the case with LAP1B where in fact it is C-terminal to the
BM1, reinforcing that the SILK motif is not important for the
interaction.
PP1 regulatory proteins can be substrates that directly
associate with the PP1 catalytic subunit, but can also be
substrate specifiers and/or targeting proteins. Having
established that LAP1B is a novel PP1 regulatory protein and
that the BM1 is responsible for the interaction, the physiological
significance of this complex was addressed.
Immunolocatization of LAP1B and PP1 (for both PP1α and
PP1γ isoforms) showed that they co-localize near the nuclear
envelope (Figure 6). These results are in agreement with PP1
interacting with LAP1B through its nucleoplasmic domain, as
discussed above. Furthermore, LAP1B is well described to
interact with lamin A/C and B1 [21,24]. Lamins are not only
located at the nuclear membrane periphery but are also found
within the nucleus [41,42]. Indeed, we showed that LAP1B co-
localizes with lamin B1 at the nuclear envelope and also in
specific intranuclear areas (Figure 6). Originally, nuclear lamins
were proposed to have a role in supporting the nuclear
envelope and binding to chromatin. However, recent reports
suggest many other roles for nuclear lamins, namely in DNA
replication, transcription, mitosis, apoptosis and cell
differentiation [43]. Potentially, and in a similar fashion, LAP1B
may be involved in other nuclear functions. LAP1B is known to
be phosphorylated during both interphase and mitosis and
several phosphorylated residues have been identified [36-38].
However, the involvement of specific kinases and/or
phosphatases had not hitherto been documented. Since we
validated the interaction between LAP1B and PP1 it is
reasonable to deduce that LAP1B may indeed be a substrate
for PP1. When PP1 is inhibited with OA a slight shift in the
LAP1B migration is observed, consistent with an increase in its
protein phosphorylation state (Figure 8). Additionally, upon
adding purified PP1γ1 protein to LAP1B immunoprecipitates,
from cells previously incubated with 500 nM OA, an increase in
the migration of LAP1B was detected, indicating that in vitro
PP1 dephosphorylates LAP1B.
Many PP1 regulators identified thus far are located in the
nucleus and are involved in diverse cellular functions, such as,
cell cycle regulation, splicing and transcription [4,5,20].
However, the only known PP1 regulator located specifically at
the nuclear membrane is AKAP-149. AKAP149 is a component
of the endoplasmic reticulum/nuclear system but the discovery
that it interacts with lamins A/C and B [44], suggests that
AKAP149 is associated with both the outer and inner nuclear
membranes. AKAP-149 recruits PP1 to the nuclear envelope
upon nuclear envelope assembly in vitro and promotes lamin B
dephosphorylation and polymerization [45,46]. Indeed, PP1
may mediate nuclear lamina reassembly, in part by
dephosphorylation of lamin B at the end of mitosis [47].
Following nuclear envelope disassembly at mitosis, LAP1B and
lamin B have similar localization and both reassemble around
the nuclear envelope during telophase [48].
In conclusion, we have identified a novel PP1 regulatory
protein, LAP1B. Both proteins co-localize in the close proximity
of the nuclear envelope. LAP1B is mainly localized to the
nuclear envelope whereas PP1 is rich in the nucleus. Co-
localization of the LAP1B:PP1 to the nuclear envelope is
indicative of specific protein recruitment for signaling events,
and this will be addressed in the future. This interaction occurs
through the REVRF motif, located in the nucleoplasmic domain
of LAP1B. Further we also determined that LAP1B is a
substrate for PP1 and PP1 in turn will dephosphorylate LAP1B.
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